Publication

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

See how QSP modeling guided the design of a reversible antibody switch that unmasks IL-12…

CertaraJuly 24, 2026

Poster

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…

CertaraJuly 20, 2026

Publication

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

QSP modeling reveals patient-specific factors driving CAR T-cell response and relapse in multiple myeloma, with…

CertaraJuly 20, 2026

On-Demand Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Watch this on-demand Q&A on using mechanistic modeling to assess feasibility and prioritize biotherapeutic candidates…

CertaraJuly 17, 2026

Webinar

Integrated mechanistic modeling approaches in oncology drug development

CertaraJuly 8, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Publication

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…

CertaraJune 4, 2026

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

CertaraJune 2, 2026

Publication

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…

CertaraJune 2, 2026

Biologics

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Integrated mechanistic modeling approaches in oncology drug development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Applying AI-Driven Biosimulation to Drug Discovery

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

Newsletter sign up

Quick links

Solutions

Contact